Skip to main content
. Author manuscript; available in PMC: 2020 Dec 29.
Published in final edited form as: Lancet Oncol. 2018 Mar 12;19(4):521–536. doi: 10.1016/S1470-2045(18)30144-X

Figure 2: Best change from baseline in tumour size over time.

Figure 2:

(A) Cohort 1 (EGFR+/ALK+ non-small-cell lung cancer [NSCLC]) patients with less than 25% of tumour cells expressing programmed cell death ligand-1 (PD-L1). (B) Cohort 1 patients with at least 25% of tumour cells expressing PD-L1. (C) Cohort 2 (EGFR−/ALK− NSCLC) patients with less than 25% of tumour cells expressing PD-L1. (D) Cohort 2 patients with at least 25% of tumour cells expressing PD-L1. (E) Cohort 3 (EGFR−/ALK− NSCLC) patients with at least 90% of tumour cells expressing PD-L1. Dashed reference lines at −30% and +20% indicate thresholds for partial response and disease progression. Values greater than 100% or less than −100% are displayed as 100% and −100%. The charts show patients evaluable for response per independent central review (all treated patients who had a baseline tumour assessment and had measurable disease at baseline according to the independent central review; patients also had to have at least one post-baseline tumour assessment to be included in the analysis). EGFR+=EGFR tyrosine kinase mutations.

ALK+=anaplastic lymphoma kinase (ALK) rearrangements. EGFR−=EGFR wild type. ALK−=ALK rearrangement negative.